Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with ...

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...